Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)

[1]  M. Bialer,et al.  Valproic acid: Second generation , 2011, Neurotherapeutics.

[2]  P. Soares-da-Silva,et al.  Eslicarbazepine acetate (BIA 2-093) , 2011, Neurotherapeutics.

[3]  C. Stafstrom,et al.  Anticonvulsant and antiepileptic actions of 2‐deoxy‐D‐glucose in epilepsy models , 2009, Annals of neurology.

[4]  M. Avoli,et al.  Neurosteroids and epileptogenesis in the pilocarpine model: Evidence for a relationship between P450scc induction and length of the latent period , 2009, Epilepsia.

[5]  F. Dudek,et al.  A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate‐induced epilepsy , 2008, Epilepsia.

[6]  D. Margineanu,et al.  Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A , 2008, British journal of pharmacology.

[7]  D. Rosillon,et al.  Effect of brivaracetam on cardiac repolarisation – a thorough QT study* , 2008, Current medical research and opinion.

[8]  K. Wilcox,et al.  In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity , 2008, Pharmacology Biochemistry and Behavior.

[9]  R. Kaminski,et al.  SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy , 2008, Neuropharmacology.

[10]  M. Devor,et al.  Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide , 2008, Neuropharmacology.

[11]  A. Falcão,et al.  Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. , 2008, International journal of clinical pharmacology and therapeutics.

[12]  A. Nehlig,et al.  FULL-LENGTH ORIGINAL RESEARCH Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS , 2008 .

[13]  J. Mayhew,et al.  Fine detail of neurovascular coupling revealed by spatiotemporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex. , 2008, Journal of neurophysiology.

[14]  M. Sargentini-Maier,et al.  Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects , 2008, Drug Metabolism and Disposition.

[15]  P. Soares-da-Silva,et al.  Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment , 2008, European Journal of Clinical Pharmacology.

[16]  J. L. Stringer,et al.  Fructose-1,6-Bisphosphate Has Anticonvulsant Activity in Models of Acute Seizures in Adult Rats , 2007, The Journal of Neuroscience.

[17]  E. Giller,et al.  Clinical Evaluation of Ganaxolone in Pediatric and Adolescent Patients with Refractory Epilepsy , 2007, Epilepsia.

[18]  J. Lambert,et al.  Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. , 2007, Pharmacology & therapeutics.

[19]  N. Mirza,et al.  Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety , 2007, Neuropharmacology.

[20]  B. Steinhoff,et al.  Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model , 2007, Neurology.

[21]  M. Bialer,et al.  An Interaction Study Between the New Antiepileptic and CNS Drug Carisbamate (RWJ‐333369) and Lamotrigine and Valproic Acid , 2007, Epilepsia.

[22]  E. Ben-Menachem,et al.  Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures , 2007, Epilepsia.

[23]  K. Papadopoulos,et al.  Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas , 2007 .

[24]  P. Rolan,et al.  The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. , 2007, British journal of clinical pharmacology.

[25]  N. Walton,et al.  Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy , 2007, Epilepsy Research.

[26]  C. Melmed,et al.  Treatment of essential tremor with the barbiturate t2000 (1,3‐dimethoxymethyl‐5,5‐diphenyl‐barbituric acid) , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  W. Alves,et al.  Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures , 2007, Neurology.

[28]  M. Lebel,et al.  Enhancement by a high fat meal of the absorption of orally administered T2000 (1,3-bismethoxymethyl-5,5-diphenylbarbituric acid; I) in man , 2007 .

[29]  M. Bialer,et al.  The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans , 2007, Drug Metabolism and Disposition.

[30]  Jing Shen,et al.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[31]  C. Elger,et al.  Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures , 2007, Epilepsia.

[32]  M. Bialer,et al.  The Effects of Central Nervous System-Active Valproic Acid Constitutional Isomers, Cyclopropyl Analogs, and Amide Derivatives on Neuronal Growth Cone Behavior , 2007, Molecular Pharmacology.

[33]  M. Fujiyoshi,et al.  Kv7.2–7.5 voltage-gated potassium channel (KCNQ2–5) opener, retigabine, reduces capsaicin-induced visceral pain in mice , 2007, Neuroscience Letters.

[34]  Tony Wu,et al.  Electrical Stimulation of the Anterior Nucleus of the Thalamus for Intractable Epilepsy: A Long‐term Follow‐up Study , 2007, Epilepsia.

[35]  A. Egberts,et al.  Valproic Acid–induced Hair‐texture Changes in a White Woman , 2007, Epilepsia.

[36]  René H. Levy,et al.  Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) , 2007, Epilepsy Research.

[37]  G. Savettieri,et al.  Levetiracetam, a new option Treatment for Creutzfeldt-Jacob Disease. , 2007 .

[38]  Alastair M. Hosie,et al.  Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites , 2006, Nature.

[39]  W. Löscher,et al.  Effects of the Novel Antiepileptic Drug Lacosamide on the Development of Amygdala Kindling in Rats , 2006, Epilepsia.

[40]  M. Bialer,et al.  Pharmacokinetics of the New Antiepileptic and CNS Drug RWJ‐333369 Following Single and Multiple Dosing to Humans , 2006, Epilepsia.

[41]  A. Richter,et al.  Antidystonic effects of Kv7 (KCNQ) channel openers in the dtsz mutant, an animal model of primary paroxysmal dystonia , 2006, British journal of pharmacology.

[42]  M. Bialer,et al.  Pharmacokinetic Interaction Study between the New Antiepileptic and CNS Drug RWJ‐333369 and Carbamazepine in Healthy Adults , 2006, Epilepsia.

[43]  Avtar Roopra,et al.  2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP–dependent metabolic regulation of chromatin structure , 2006, Nature Neuroscience.

[44]  J. Walden,et al.  An Exploratory Open Trial on Safety and Efficacy of the Anticonvulsant Retigabine in Acute Manic Patients , 2006, Journal of clinical psychopharmacology.

[45]  Giuseppe Biagini,et al.  Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy , 2006, Experimental Neurology.

[46]  W. Cawello,et al.  640 LOW POTENTIAL FOR DRUG‐DRUG‐INTERACTION OF LACOSAMIDE , 2006 .

[47]  R. Sankar,et al.  Regulation of Kindling Epileptogenesis by Hippocampal Galanin Type 1 and Type 2 Receptors: The Effects of Subtype-Selective Agonists and the Role of G-Protein-Mediated Signaling , 2006, Journal of Pharmacology and Experimental Therapeutics.

[48]  G. Lees,et al.  Seeking a mechanism of action for the novel anticonvulsant lacosamide , 2006, Neuropharmacology.

[49]  M. Bialer.  New antiepileptic drugs that are second generation to existing antiepileptic drugs , 2006, Expert opinion on investigational drugs.

[50]  V. Caprio,et al.  A radical mediated approach to the core structure of huperzine A , 2006 .

[51]  C. Wasterlain,et al.  Brivaracetam Is A Potent Anticonvulsant In Experimental Status Epilepticus: 2.381 , 2005 .

[52]  D. Strøbæk,et al.  Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels , 2005, Journal of Pharmacology and Experimental Therapeutics.

[53]  A. Mazarati,et al.  Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors , 2005, Neuropeptides.

[54]  Holger Lerche,et al.  The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate , 2005, Molecular Pharmacology.

[55]  K. Akcali,et al.  The Role of bcl‐2 Family of Genes During Kindling , 2005, Epilepsia.

[56]  W. Cawello,et al.  Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender , 2004 .

[57]  C. Baumgartner,et al.  Reduction of Hippocampal Collapsin Response Mediated Protein-2 in Patients with Mesial Temporal Lobe Epilepsy , 2004, Neurochemical Research.

[58]  J. McNamara,et al.  Conditional Deletion of TrkB but Not BDNF Prevents Epileptogenesis in the Kindling Model , 2004, Neuron.

[59]  M. Rogawski,et al.  Allopregnanolone Analogs That Positively Modulate GABAA Receptors Protect against Partial Seizures Induced by 6‐Hz Electrical Stimulation in Mice , 2004, Epilepsia.

[60]  J. Rho,et al.  Epilepsy : scientific foundations of clinical practice , 2004 .

[61]  C. Rundfeldt,et al.  The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[62]  C. Mathiesen,et al.  Pharmacological characterisation of acid-induced muscle allodynia in rats. , 2004, European journal of pharmacology.

[63]  M. Knip,et al.  Thyroid Function in Girls with Epilepsy with Carbamazepine, Oxcarbazepine, or Valproate Monotherapy and after Withdrawal of Medication , 2004, Epilepsia.

[64]  G. Bennett,et al.  Stereoselective Pharmacokinetics and Pharmacodynamics of Propylisopropyl Acetamide, a CNS-Active Chiral Amide Analog of Valproic Acid , 1999, Pharmaceutical Research.

[65]  M. Rogawski,et al.  Neurosteroids: Endogenous Modulators of Seizure Susceptibility , 2004 .

[66]  M. Leśkiewicz,et al.  Inhibitory effect of some neuroactive steroids on cocaine-induced kindling in mice. , 2003, Polish journal of pharmacology.

[67]  R. B. Carter,et al.  Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. , 2003, European journal of pharmacology.

[68]  A. Zangara.  The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease , 2003, Pharmacology Biochemistry and Behavior.

[69]  Collin A Hovinga.  SPM-927 (Schwarz Pharma). , 2003, IDrugs : the investigational drugs journal.

[70]  D. A. Brown,et al.  Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells , 2003, The Journal of physiology.

[71]  G. Bennett,et al.  Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents , 2003, British journal of pharmacology.

[72]  B. Jensen,et al.  The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. , 2003, European journal of pharmacology.

[73]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI) , 2002, Epilepsy Research.

[74]  P. Soares-da-Silva,et al.  The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine , 2002, Neurochemistry International.

[75]  K. Wilcox,et al.  Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. , 2002, Molecular pharmacology.

[76]  C. Prueter,et al.  Dissociative and Associated Psychopathological Symptoms in Patients with Epilepsy, Pseudoseizures, and Both Seizure Forms , 2002, Epilepsia.

[77]  T. Bártfai,et al.  Book Review: Galanin: An Endogenous Anticonvulsant? , 2001 .

[78]  M. Barton,et al.  Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy , 2001, Epilepsy Research.

[79]  Tao Xu,et al.  SV2 modulates the size of the readily releasable pool of secretory vesicles , 2001, Nature Cell Biology.

[80]  D. A. Brown,et al.  Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.

[81]  M. Bialer,et al.  Anticonvulsant Profile of Valrocemide (TV1901): A New Antiepileptic Drug , 2001, Epilepsia.

[82]  A. A. Parsons,et al.  Tonabersat (SB‐220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve‐induced neurovascular reflexes , 2001, British journal of pharmacology.

[83]  A. A. Parsons,et al.  Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan , 2001, Brain Research.

[84]  B. Bourgeois,et al.  Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial , 2000, Epilepsy Research.

[85]  M. Rogawski,et al.  Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. , 2000, The Journal of pharmacology and experimental therapeutics.

[86]  K. Laxer,et al.  Assessment of Ganaxolone's Anticonvulsant Activity Using a Randomized, Double‐Blind, Presurgical Trial Design , 2000, Epilepsia.

[87]  S. Burbidge,et al.  Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. , 2000, Molecular pharmacology.

[88]  R. Netzer,et al.  The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits , 2000, Neuroscience Letters.

[89]  M. I. Smith,et al.  SB-220453, A Potential Novel Antimigraine Agent, Inhibits Nitric Oxide Release Following Induction of Cortical Spreading Depression in the Anaesthetized Cat , 2000, Cephalalgia : an international journal of headache.

[90]  U. Heinemann,et al.  Effects of Retigabine (D‐23129) on Different Patterns of Epileptiform Activity Induced by Low Magnesium in Rat Entorhinal Cortex Hippocampal Slices , 2000, Epilepsia.

[91]  U. Heinemann,et al.  Retigabine strongly reduces repetitive firing in rat entorhinal cortex. , 1999, European journal of pharmacology.

[92]  C. Rundfeldt,et al.  The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation , 1999, Epilepsy Research.

[93]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) , 1999, Epilepsy Research.

[94]  A. A. Parsons,et al.  Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent. , 1999, Bioorganic & medicinal chemistry letters.

[95]  U. Heinemann,et al.  Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[96]  R. Sankar,et al.  Galanin Modulation of Seizures and Seizure Modulation of Hippocampal Galanin in Animal Models of Status Epilepticus , 1998, The Journal of Neuroscience.

[97]  H. Klitgaard,et al.  Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man , 1998, Epilepsy Research.

[98]  G. Kinney,et al.  Galanin Receptor-Mediated Inhibition of Glutamate Release in the Arcuate Nucleus of the Hypothalamus , 1998, The Journal of Neuroscience.

[99]  E. Monaghan,et al.  Initial Human Experience with Ganaxolone, a Neuroactive Steroid with Antiepileptic Activity , 1997, Epilepsia.

[100]  D. Middlemiss,et al.  Characterization of the binding of [3H]‐SB‐204269, a radiolabelled form of the new anticonvulsant SB‐204269, to a novel binding site in rat brain membranes , 1997, British journal of pharmacology.

[101]  R. B. Carter,et al.  Characterization of the anticonvulsant properties of Ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acid(A) receptor , 1997 .

[102]  C. Rundfeldt,et al.  D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. , 1996, European journal of pharmacology.

[103]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[104]  G. Telegdy,et al.  Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats , 1992, Brain Research.

[105]  P. Taylor,et al.  A novel approach to the site specific delivery of potential HMG-CoA reductase inhibitors , 1992 .

[106]  M. Bialer.  Clinical Pharmacology of Valpromide , 1991, Clinical pharmacokinetics.

[107]  G. Newman,et al.  Kinetic Model of 2-Deoxyglucose Metabolism Using Brain Slices , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[108]  K. Dretchen,et al.  Protection by phenytoin and calcium channel blocking agents against the toxicity of diisopropylfluorophosphate. , 1986, Toxicology and applied pharmacology.

[109]  K. Dretchen,et al.  Diphenylbarbituric Acid: Its Effects on Neuromuscular and Spinal Cord Function in the Cat , 1985, Epilepsia.

[110]  J. Huguenard,et al.  Suppression of repetitive firing of neurons by diphenylbarbituric acid. , 1985, The Journal of pharmacology and experimental therapeutics.

[111]  D. Kerr,et al.  The 2-Deoxyglucose Test as a Supplement to Fasting for Detection of Childhood Hypoglycemia , 1984, Pediatric Research.

[112]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[113]  B. Gallagher,et al.  The Effects of 5,5‐Diphenylbarbituric Acid on Experimental Seizures in Rats: Correlation Between Plasma and Brain Concentrations and Anticonvulsant Activity , 1975, Epilepsia.

[114]  D. Pace,et al.  A comparison of the anticonvulsant, neurotoxic and lethal effects of diphenylbarbituric acid, phenobarbital and diphenylhydantoin in the mouse. , 1973, The Journal of pharmacology and experimental therapeutics.

[115]  C. H. Ellis,et al.  Comparative central depressant actions of some 5-phenyl-5-alkyl barbituric acids. , 1947, The Journal of pharmacology and experimental therapeutics.

[116]  H. Merritt,et al.  EXPERIMENTAL DETERMINATION OF ANTICONVULSIVE ACTIVITY OF CHEMICAL COMPOUNDS , 1945 .

[117]  P. Knoefel,et al.  THE ANTICONVULSANT ACTION OF DIPHENYL HYDANTOIN AND SOME RELATED COMPOUNDS , 1942 .

[118]  H. Houston Merritt,et al.  A NEW SERIES OF ANTICONVULSANT DRUGS TESTED BY EXPERIMENTS ON ANIMALS , 1938 .

[119]  S. McElvain.  5,5-Diphenylbarbituric Acid , 1935 .